@article{discovery1479100, month = {December}, pages = {1563--1576}, journal = {European Respiratory Journal}, note = {The content of this work is copyright of the authors or their employers. Design and branding are copyright {\copyright}ERS 2015. ERJ Open articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0}, publisher = {EUROPEAN RESPIRATORY SOC JOURNALS LTD}, volume = {46}, year = {2015}, title = {Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries}, number = {6}, author = {Getahun, H and Matteelli, A and Abubakar, I and Aziz, MA and Baddeley, A and Barreira, D and Den Boon, S and Borroto Gutierrez, SM and Bruchfeld, J and Burhan, E and Cavalcante, S and Cedillos, R and Chaisson, R and Chee, CB-E and Chesire, L and Corbett, E and Dara, M and Denholm, J and de Vries, G and Falzon, D and Ford, N and Gale-Rowe, M and Gilpin, C and Girardi, E and Go, U-Y and Govindasamy, D and Grant, AD and Grzemska, M and Harris, R and Horsburgh, CR and Ismayilov, A and Jaramillo, E and Kik, S and Kranzer, K and Lienhardt, C and LoBue, P and Loennroth, K and Marks, G and Menzies, D and Migliori, GB and Mosca, D and Mukadi, YD and Mwinga, A and Nelson, L and Nishikiori, N and Oordt-Speets, A and Rangaka, MX and Reis, A and Rotz, L and Sandgren, A and Schepisi, MS and Schuenemann, HJ and Sharma, SK and Sotgiu, G and Stagg, HR and Sterling, TR and Tayeb, T and Uplekar, M and van der Werf, MJ and Vandevelde, W and van Kessel, F and van't Hoog, A and Varma, JK and Vezhnina, N and Voniatis, C and Noordegraaf-Schouten, MV and Weil, D and Weyer, K and Wilkinson, RJ and Yoshiyama, T and Zellweger, JP and Raviglione, M}, url = {http://dx.doi.org/10.1183/13993003.01245-2015}, abstract = {Latent tuberculosis infection (LTBI) is characterised by the presence of immune responses to previously acquired Mycobacterium tuberculosis infection without clinical evidence of active tuberculosis (TB). Here we report evidence-based guidelines from the World Health Organization for a public health approach to the management of LTBI in high risk individuals in countries with high or middle upper income and TB incidence of {\ensuremath{<}}100 per 100 000 per year. The guidelines strongly recommend systematic testing and treatment of LTBI in people living with HIV, adult and child contacts of pulmonary TB cases, patients initiating anti-tumour necrosis factor treatment, patients receiving dialysis, patients preparing for organ or haematological transplantation, and patients with silicosis. In prisoners, healthcare workers, immigrants from high TB burden countries, homeless persons and illicit drug users, systematic testing and treatment of LTBI is conditionally recommended, according to TB epidemiology and resource availability. Either commercial interferon-gamma release assays or Mantoux tuberculin skin testing could be used to test for LTBI. Chest radiography should be performed before LTBI treatment to rule out active TB disease. Recommended treatment regimens for LTBI include: 6 or 9 month isoniazid; 12 week rifapentine plus isoniazid; 3-4 month isoniazid plus rifampicin; or 3-4 month rifampicin alone.}, issn = {0903-1936}, keywords = {Science \& technology, life sciences \& biomedicine, respiratory system, cost-effectiveness analysis, multidrug-resistant tuberculosis, randomized controlled-trial, preventive therapy, close contacts, public-health, follow-up, homeless adults, United-States, drug-users.} }